Cargando…

Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort

BACKGROUND: There is no clear consensus on the optimal systemic treatment regimen in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) patients. We describe clinical characteristics and outcome of cHCC-CCA patients, with a special focus on patients receiving palliative systemic therapy, includin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pomej, K., Balcar, L., Shmanko, K., Welland, S., Himmelsbach, V., Scheiner, B., Mahyera, A., Mozayani, B., Trauner, M., Finkelmeier, F., Weinmann, A., Vogel, A., Pinter, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024130/ https://www.ncbi.nlm.nih.gov/pubmed/36753993 http://dx.doi.org/10.1016/j.esmoop.2023.100783

Ejemplares similares

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients
por: Balcar, Lorenz, et al.
Publicado: (2023)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital
por: Pomej, Katharina, et al.
Publicado: (2021)

Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
por: de Castro, Tiago, et al.
Publicado: (2022)

Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers
por: Himmelsbach, Vera, et al.
Publicado: (2022)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy
por: Scheiner, Bernhard, et al.
Publicado: (2023)

Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience
por: Sinner, Friedrich, et al.
Publicado: (2022)

Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Plasma exchange for treatment of a therapy‐related thrombotic microangiopathy in a patient with advanced hepatocellular carcinoma—A case report
por: Stortz, Marco, et al.
Publicado: (2023)

Alpha‐fetoprotein‐adjusted‐to‐HCC‐size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma
por: Meischl, Tobias, et al.
Publicado: (2021)

Mixed Hepatocellular Cholangiocarcinoma: A Comparison of Survival between Mixed Tumors, Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma from a Single Center
por: Penzkofer, Lea, et al.
Publicado: (2023)

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
por: Hartl, Lukas, et al.
Publicado: (2021)

Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
por: Pinter, Matthias, et al.
Publicado: (2021)

Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2018)

Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study
por: Kim, Jongman, et al.
Publicado: (2023)

Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma
por: Murugesan, Karthikeyan, et al.
Publicado: (2021)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Current update on combined hepatocellular-cholangiocarcinoma
por: Maximin, Suresh, et al.
Publicado: (2014)

Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma
por: Himmelsbach, Vera, et al.
Publicado: (2021)

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma
por: Renzulli, Matteo, et al.
Publicado: (2021)

Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Massarweh, Nader N., et al.
Publicado: (2017)

Reduced Lipid Peroxidation Predicts Unfavorable Prognosis in Hepatocellular Carcinoma, but Not Intrahepatic Cholangiocarcinoma
por: Gerber, Tiemo Sven, et al.
Publicado: (2023)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
por: Casadio, M., et al.
Publicado: (2022)

Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Kis, Bela, et al.
Publicado: (2017)

Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Burkhart, Richard A., et al.
Publicado: (2017)

Geographic Variation of Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Hepatocellular Carcinoma in the United States
por: Altekruse, Sean F., et al.
Publicado: (2015)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
por: Alonso-Peña, Marta, et al.
Publicado: (2019)

Synchronous Hepatocellular Carcinoma and Cholangiocarcinoma in a Patient Transplanted for Cryptogenic Cirrhosis
por: Geramizadeh, B., et al.
Publicado: (2014)

Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
por: Brandão, Ajacio Bandeira de Mello, et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular‐cholangiocarcinoma after resection
por: Song, Peipei, et al.
Publicado: (2019)

Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
por: Auer, Timo Alexander, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vhpfggj7g6j3i9g4f7mhq3h5fe